Preeclampsia (PE) is a pregnancy-specific hypertensive disorder characterized by systemic endothelial dysfunction, in which alterations in nitric oxide (NO) signaling may play an important role. This study aimed to evaluate longitudinal changes in endothelial NO bioavailability and plasma asymmetric dimethylarginine (ADMA) levels in pregnant women at increased risk of PE. Participants were derived from the prospective ECLIPSE-Brazil cohort and were evaluated across four gestational periods: 12–19, 20–29, 30–34, and >34 weeks. Pregnancy outcomes were available for 165 women, of whom 120 remained non-preeclamptic and 45 developed PE. In an analytical subcohort, NO bioavailability was assessed in vitro in endothelial cells exposed to maternal plasma, while ADMA was measured by enzyme-linked immunosorbent assay. Women who subsequently developed PE showed significantly lower NO bioavailability at 12–19 weeks (p34 weeks (p=0.025) compared with women who remained non-preeclamptic. In contrast, plasma ADMA concentrations did not differ significantly between groups at any gestational period. These findings demonstrate a gestational age-dependent alteration in endothelial NO bioavailability associated with PE development. The early reduction in NO, followed by increased bioavailability later in pregnancy, suggests dynamic dysregulation of endothelial NO signaling that may precede clinical manifestations of PE and appears to occur independently of circulating ADMA levels.